Pediatrix Reaffirms 2023 Adjusted EBITDA Guidance Of $235M-$245M Compared To 2022 Adjusted EBITDA Of $241.03M
Portfolio Pulse from Benzinga Newsdesk
Pediatrix has reaffirmed its 2023 adjusted EBITDA guidance of $235M-$245M, compared to its 2022 adjusted EBITDA of $241.03M.
August 04, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pediatrix, listed as MD, has reaffirmed its 2023 EBITDA guidance, which is slightly lower than its 2022 EBITDA.
Pediatrix's reaffirmed EBITDA guidance for 2023 is slightly lower than its 2022 EBITDA. This could potentially indicate a slowdown in growth or profitability, which may negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100